TriangleNCT01445080 · OUTCOME
Mean Concentration of VEGF2
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- cells/ml
- Interval / dispersion
- Standard Deviation
- Time frame
- 28 days
What was measured
Mean concentration of VEGF2 in peripheral blood sample.
Analysis population: Data were not collected for Part A: 250 mg/m\^2, Part B:150 mg/m\^2, Part B: 200 mg/m\^2, and Part C:150 mg/m\^2
Groups in this outcome
Part A: Refractory Solid Tumors: BAY 43-9006 105 mg/m^2
Patients receive oral sorafenib 105 mg/m\^2 every 12 hours.
Part A: Refractory Solid Tumors: BAY 43-9006 130 mg/m^2
Patients receive oral sorafenib 130 mg/m\^2 every 12 hours.
Part A: Refractory Solid Tumors: BAY 43-9006 150 mg/m^2
Patients receive oral sorafenib 150 mg/m\^2 every 12 hours.
Part A: Refractory Solid Tumors: BAY 43-9006 200 mg/m^2
Patients receive oral sorafenib 200 mg/m\^2 every 12 hours.
PK Cohort Expanded: BAY 43-9006 200 mg/m^2
Patients receive oral sorafenib 200 mg/m\^2 every 12 hours.
| Group | Source count |
|---|---|
| Part A: Refractory Solid Tumors: BAY 43-9006 105 mg/m^2 | 4 |
| Part A: Refractory Solid Tumors: BAY 43-9006 130 mg/m^2 | 2 |
| Part A: Refractory Solid Tumors: BAY 43-9006 150 mg/m^2 | 5 |
| Part A: Refractory Solid Tumors: BAY 43-9006 200 mg/m^2 | 3 |
| PK Cohort Expanded: BAY 43-9006 200 mg/m^2 | 4 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part A: Refractory Solid Tumors: BAY 43-9006 105 mg/m^2 | 2650 | 2243.49 | Not reported | Not reported | Not reported |
| Part A: Refractory Solid Tumors: BAY 43-9006 130 mg/m^2 | 247.5 | 258.09 | Not reported | Not reported | Not reported |
| Part A: Refractory Solid Tumors: BAY 43-9006 150 mg/m^2 | 3531.5 | 4775.11 | Not reported | Not reported | Not reported |
| Part A: Refractory Solid Tumors: BAY 43-9006 200 mg/m^2 | 430 | 324.50 | Not reported | Not reported | Not reported |
| PK Cohort Expanded: BAY 43-9006 200 mg/m^2 | 100 | 124.90 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 2243.49
- value
- 2650
- group Id
- OG001
- spread
- 258.09
- value
- 247.5
- group Id
- OG002
- spread
- 4775.11
- value
- 3531.5
- group Id
- OG003
- spread
- 324.50
- value
- 430
- group Id
- OG004
- spread
- 124.90
- value
- 100
- denoms
- counts
- group Id
- OG000
- value
- 4
- group Id
- OG001
- value
- 2
- group Id
- OG002
- value
- 5
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 4
- units
- Participants
- description
- Mean concentration of VEGF2 in peripheral blood sample.
- dispersion Type
- Standard Deviation
- groups
- description
- Patients receive oral sorafenib 105 mg/m\^2 every 12 hours.
- id
- OG000
- title
- Part A: Refractory Solid Tumors: BAY 43-9006 105 mg/m^2
- description
- Patients receive oral sorafenib 130 mg/m\^2 every 12 hours.
- id
- OG001
- title
- Part A: Refractory Solid Tumors: BAY 43-9006 130 mg/m^2
- description
- Patients receive oral sorafenib 150 mg/m\^2 every 12 hours.
- id
- OG002
- title
- Part A: Refractory Solid Tumors: BAY 43-9006 150 mg/m^2
- description
- Patients receive oral sorafenib 200 mg/m\^2 every 12 hours.
- id
- OG003
- title
- Part A: Refractory Solid Tumors: BAY 43-9006 200 mg/m^2
- description
- Patients receive oral sorafenib 200 mg/m\^2 every 12 hours.
- id
- OG004
- title
- PK Cohort Expanded: BAY 43-9006 200 mg/m^2
- param Type
- MEAN
- population Description
- Data were not collected for Part A: 250 mg/m\^2, Part B:150 mg/m\^2, Part B: 200 mg/m\^2, and Part C:150 mg/m\^2
- reporting Status
- POSTED
- time Frame
- 28 days
- title
- Mean Concentration of VEGF2
- type
- SECONDARY
- unit Of Measure
- cells/ml
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice